VYNE Therapeutics Inc.

NASDAQ: VYNE · Real-Time Price · USD
0.40
-1.04 (-72.22%)
At close: Jul 30, 2025, 3:59 PM

VYNE Therapeutics Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-39.83M -28.45M -23.21M -73.33M
Depreciation & Amortization
4K n/a 72K 109K
Stock-Based Compensation
3.3M 3.31M 4.3M 8.08M
Other Working Capital
-114K 214K -349K -371K
Other Non-Cash Items
-2.44M -254K -12.64M 2.47M
Deferred Income Tax
n/a n/a n/a 1.52M
Change in Working Capital
5M 60K 2.28M 4.78M
Operating Cash Flow
-33.97M -25.34M -29.2M -56.37M
Capital Expenditures
-117K n/a n/a n/a
Cash Acquisitions
n/a 5M 15.67M n/a
Purchase of Investments
-60.52M -62.35M n/a n/a
Sales Maturities Of Investments
84M n/a n/a 1.03M
Other Investing Acitivies
n/a n/a 15.67M n/a
Investing Cash Flow
23.36M -57.35M 15.67M 1.03M
Debt Repayment
n/a n/a n/a -36.43M
Common Stock Repurchased
n/a -360K n/a n/a
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
-141K -67K -28K 228K
Financial Cash Flow
-141K 82.39M 1.65M 39.78M
Net Cash Flow
-10.75M -301K -11.88M -15.56M
Free Cash Flow
-34.09M -25.34M -29.2M -56.37M